Epstein-Barr Virus Markers in Nasopharyngeal Carcinoma

  • Alberto Faggioni
  • Giuseppe Barile
  • Mario Piccoli
  • Luigi Frati


Nasopharyngeal carcinoma (NPC) is, along with Burkitt’s lymphoma (BL), one of the two human cancers which are thought to be associated with the Epstein-Barr virus (EBV), the etiological agent of infectious mononucleosis. The EBV was first discovered by M.A. Epstein in a Burkitt’s lymphoma (Epstein et al., 1964), and its association with NPC was casual, when testing for anti-EBV antibodies sera of BL patients and using nasopharyngeal carcinoma sera as controls, it was seen that both series of sera contained high levels of EBV antibodies (Old et al., 1966). Now the constant presence of EBV DNA in the tumor tissue strenghtens this association of EBV with NPC.


Nasopharyngeal Carcinoma Infectious Mononucleosis Antibody Dependent Cellular Cytotoxicity Viral Capsid Antigen Virus Induce Cell Fusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ablashi, D., Allal, L., Armstrong, G., Bouguermou, A., Pearson, G., Levine, P., Bengali, Z., Easton, J., Zaghouani, S., Chouter, A. and Ghoudali, R., 1981, Some characteristics of Nasopharyngeal carcinoma in Algeria, in: “Nasopharyngeal carcinoma, Grundman et al. eds., Gustav Fischer Verlag, Stuttgart, New York, 157.Google Scholar
  2. Bayliss, G.J. and Wolf, H., 1980, Epstein-Barr virus induced cell fusion. Nature, 287, 164.PubMedCrossRefGoogle Scholar
  3. Chan, S.H., Levine, P.H., DeThe’, G., Mulroney, S., Lavoue, M., Glen, S., Goh, E., Connelly, R., 1979, A comparison of the prognostic value of antibody dependent cellular cytotoxicity and other EBV antibodies in Chinese patients with nasopharyngeal carcinoma. Int. J. Cancer, 23, 181Google Scholar
  4. Chan, S.H. and Chew, T.S., 1981, Lack of regression in Epstein-Barr virus infected leukocyte cultures of nasopharyngeal carcinoma patients. Lancet, 2, 1353.PubMedCrossRefGoogle Scholar
  5. Desgranges, C., Bornkamm, G., Zeng, Y., Wang, P., Zhu, J., Shang, M. and DeThe’, G., 1982, Detection of Epstein-Barr viral DNA internal repeats in the nasopharyngeal mucosa of Chinese with IgA/EBV specific antibodies. Int. J. Cancer, 29, 87.Google Scholar
  6. Epstein, M.A., Achong, B.G. and Barr, Y.M., 1964, Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet, 1, 7.Google Scholar
  7. Faggioni, A., Ablashi, D., Armstrong, G., Dahlberg, J., Sundar, S., Rice, J. and Donovan, P., Enhancing effect of N-methyl-N-nitro -N-nitrosoguanidine (MNNG) on Epstein-Barr virus (EBV) replication and comparison of short term and continuous TPA treatment of producer and nonproducer cells for EBV antigen induction and/or stimulation. In: “Nasopharyngeal carcinoma: current concepts”, Prasad et al. eds., in press.Google Scholar
  8. Glaser, R., Nonoyama, M., Shows, T.B., Henle, G., Henle, W., 1975 Epstein-Barr virus: Studies on the association of virus genome with human chromosomes in hybrid cells. In: “Oncogenesis and Herpesviruses II, DeThe’ et al. eds., IARC, Lyon, 457.Google Scholar
  9. Glaser, R., Ablashi, D., Nonoyama, M., Henle, W., Easton, J., Fel- lows, C., Armstrong, G., 1977, Enhanced oncogenic behaviour of human and mouse cells following cellular hybridization with Burkitt’s tumor cells. Proc.Natl.Acad.Sci. USA, 74, 2574.Google Scholar
  10. Hellstrom, K.E., and Hellstrom, I., 1969, Cellular immunity against tumor antigens. Adv. Cancer Research, 12, 167.Google Scholar
  11. Henle, G. and Henle, W., 1966, Immunofluorescence in cells derived from Burkitt’s lymphoma. J. Bact., 91, 1248.PubMedGoogle Scholar
  12. Henle, G., Henle, W., and Klein, G., 1971, Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus infected cells. Int. J. Cancer, 8, 272.Google Scholar
  13. Henle, W., Ho, H., Henle, G., Chan, J, Kwan, H., 1977, Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virusGoogle Scholar
  14. related antibody patterns following therapy. Int. J. Cancer, 20, 663.Google Scholar
  15. Henle, W., Henle, G., 1978, The immunological approach to study of possible virus-induced human malignancies using the Epste-in-Barr virus as an example. Prog. Expt. Tumor Res., 21, 19.Google Scholar
  16. Ho, J.H.C., 1972, Nasopharyngeal carcinoma. Adv. Cancer Res. 15, 7.Google Scholar
  17. Ho, J.H.C., Chau, J., Tse, K.C., Levine, P.H., 1978, In vivo cell mediated immunity in Chinese patients with nasopharyngeal carcinoma. In: “Nasopharyngeal carcinoma: etiology and control” DeThe’ et al. eds., IARC, Lyon, 545.Google Scholar
  18. Huang, D.P., Ho, J.H.C., Saw, D., and Teoh, T.B., 1978, Carcinoma of the nasal and paranasal regions in rats fed with CantoneseGoogle Scholar
  19. salted marine fish. In: “Nasopharyngeal carcinoma: etiology and control”, DeThe’ et al. eds., IARC, Lyon, 315.Google Scholar
  20. Ito, Y., Yanase, S., Fujita, J., Harayama, T., Takashima, M., and Imanaka, H., 1981, A short term in vitro assay for promoter substances using human lymphoblastoid cells latently infected with Epstein-Barr virus. Cancer Lett., 13, 29.PubMedCrossRefGoogle Scholar
  21. Lanier, A.P., Henle, W., Bender, T.R., Henle, G. and Talbot, M.L., 1980, Epstein-Barr virus specific antibody titers in seven A-laskan natives before and after diagnosis of nasopharyngeal carcinoma. Int. J. Cancer, 26, 133.Google Scholar
  22. Levine, P.H., DeThe’, G., Brugere, J., Schwabb, G., Mourali, N., Herbermann, R., Ambrosioni, J., Revol, P., 1978, Delayed hypersensitivity reactions of cancer patients to antigens of lymphoid cell lines. Int. J. Cancer, 22, 400.Google Scholar
  23. Levine, P.H., Pizza, G., Cannon, G., Ablashi, D., Armstrong, G., Viza, D., 1981, Cell-Mediated immunity to Epstein-Barr virus associated membrane antigens in patients with nasopharyngeal carcinoma. In: “Nasopharyngeal carcinoma”, Grundmann et al., eds., Springer Fischer Verlag, Stuttgrart, New York, 137.Google Scholar
  24. Kamaraju, L., Levine, P., Sundar, S., Ablashi, D., Faggioni, A., Armstrong, G., Bertram, G. and Krueger, G., 1983, Epstein-Barr virus related lymphocyte stimulation inhibitor. A possible prognostic tool for nasopharyngeal carcinoma. JNCI, 70, 643.Google Scholar
  25. King, H. and Heinszel, K., 1972, Cancer mortality among foreign and native born Chinese in the United States. J. Chronic. Dis. 26, 623.Google Scholar
  26. Moss, D.J., Rickinson, A.B. and Pope, J.H., 1978, Long term T-cell mediated immunity to EBV in man. I. Complete regression of virus induced transformation in cultures of seropositive donor leukocytes. Int. J. Cancer, 22, 662.Google Scholar
  27. Ng, W.S., Ng, M.H., Ho, H.C., Lamelin, P., 1977, In vitro immune response to PPD extracts from Raji cells and nasopharyngeal carcinoma biopsies in nasopharyngeal carcinoma leukocytes. Br. J. Cancer, 36, 713.Google Scholar
  28. Notkins, A.L., 1974, Immune mechanisms by which the spread of viral infections is stopped. Cell. Immunol., 11, 478.Google Scholar
  29. Old, J.L, Boyse, E.A., Oettgen, H.F., Geering, G., Williamson, B., Clifford, P., 1966, Precipitating antibody in human serum to an antigen present in cultured Burkitt’s lymphoma cells. Proc. Natl.Acad.Sci. USA, 56, 1699.Google Scholar
  30. Pearson, G. and Orr, T.W., 1976, Antibody dependent cellular cytotoxicity against cells expressing Epstein-Barr virus antigens. JNCI, 56, 485.PubMedGoogle Scholar
  31. Pearson, G., Johanson, B. and Klein, G., 1978, Antibody dependent cellular cytotoxicity against Epstein-Barr virus associated antigens in African patients with nasopharyngeal carcinoma. Int. J. Cancer, 22, 120.Google Scholar
  32. Pearson, G., Weiland, L., Neel, H.B., 1 981, Evaluation of antibodies to EBV in the diagnosis of American nasopharyngeal carcinoma. In: “Nasopharyngeal Carcinoma”, Grundmann et al, eds., Gustav Fischer Verlag, Stuttgart, New York, 231.Google Scholar
  33. Reedman, B.M. and Klein, G., 1973, Cellular localization of an EBV associated complement fixing antigen in producer and non producer lymphoblastoid cell lines. Int. J. Cancer, 11, 499.Google Scholar
  34. Simons, M.J., Wee, G.B., Chan, S., Shanmugaratnam, K., Day, N., DeThe’, G., 1975, Probable identification on an HLA second-locus antigen associated with an high risk of a nasopharyngeal carcinoma, Lancet, 1, 142.PubMedCrossRefGoogle Scholar
  35. Sundar, S., Ablashi, D., Kamaraju, L., Levine, P.H., Faggioni, A., Armstrong, G., Pearson, G., Krueger, G., Hewetson, J., Bertram, G., Sestherhenn, K. and Menezes, J., 1982, Sera from patients with undifferentiated nasopharyngeal carcinoma contain a factor which abrogates specific Epstein-Barr virus antigen induced lymphocyte response. Int. J. Cancer, 29, 407.Google Scholar
  36. Zeng, Yi., Liu, Yuxi., Liu, Chunren, Chen, S., Wei, J., Zhu, J., Zai, H., 1980, Application of an immunoenzymatic and an immunoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology, 13, 162.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Alberto Faggioni
    • 1
  • Giuseppe Barile
    • 1
  • Mario Piccoli
    • 1
  • Luigi Frati
    • 1
  1. 1.Istituto di Patologia GeneraleUniversità degli Studi di Roma “La Sapienza”Italy

Personalised recommendations